GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Net Income From Continuing Operations

Embecta (FRA:JX7) Net Income From Continuing Operations : €65 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Embecta's net income from continuing operations for the three months ended in Mar. 2024 was €27 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €65 Mil.

Embecta Net Income From Continuing Operations Historical Data

The historical data trend for Embecta's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Net Income From Continuing Operations Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Net Income From Continuing Operations
392.26 363.03 352.58 225.84 65.97

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.08 14.03 5.62 18.43 26.59

Embecta Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embecta (FRA:JX7) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Net Income From Continuing Operations
Comparable Companies
LMAT ATRI BLFS OSUR ANIK UTMD WRBY ANGO PLSE SMTI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC WST OCSE:COLO B RMD TSE:4543 XSWX:STMN
Traded in Other Exchanges
EMBC:USA JX7:Germany
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Website
https://www.embecta.com
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta (FRA:JX7) Headlines

No Headlines